DEA Places Pain Medicine Into Schedule II
The Drug Enforcement Administration is placing the newly approved drug oliceridine in Schedule II of the Controlled Substances Act, it said in an interim final rule released Oct. 29. Effective Oct. 30, oliceridine, which was granted approval by FDA in…
Sign up for a free preview to unlock the rest of this article
Export Compliance Daily combines U.S. export control news, foreign border import regulation and policy developments into a single daily information service that reliably informs its trade professional readers about important current issues affecting their operations.
August, is subject to new registration, labeling, record-keeping, and import and export requirements. DEA is accepting comments on the rule until Nov. 30.